[ad_1]
TBE/iStock Editorial via Getty Images
Novartis (NYSE:NVS) said the U.S. Court of Appeals for the Federal Circuit has upheld the company’s U.S. combination patent for its blockbuster cardiac drug Entresto, also known as sacubitril/valsartan.
The Swiss drugmaker said it will work to enforce the patent
[ad_2]
